06.11.2012 - Ziarco has raised €21.1m in a series A financing round. The start-up from four former Pfizer colleagues gets the money from their former employer.
Ziarco Pharma Ltd. from Canterbury secured €21.1m (GBP16.8m) in a series A financing round. Investors are US venture fund Biotechnology Value Fund L.P. and other affiliates of BVF Partners L.P. (“BVF”) as well as Pfizer Venture Investments (“PVI”). Ziarco is a new clinical-stage biotechnology company founded by President and CEO Mike Yeadon, a former Vice President and Chief Scientific Officer of Pfizer’s Allergy and Respiratory Research Unit in Sandwich. Together with three former Pfizer colleagues, he directs the start-up which aims to develop innovative therapeutics targeting inflammatory and allergic diseases. One of the peers, CSO Steve Liu, claims that the most advanced clinical programme, ZPL-3893787 – a histamine H4 receptor (H4R) antagonist – could potentially be used to treat several major diseases, including asthma, allergic rhinitis, pain and a variety of inflammatory skin conditions. This programme is included in a deal made by Ziarco and Pfizer Inc. that promises the start-up exclusive worldwide rights to commercialise a range of clinical, preclinical and research assets. In return, Pfizer will receive equity as well as certain product-based milestone and royalty payments.
The lead compound of the H4R antagonist programme has completed a Phase I multiple ascending dose study. Other programmes in various stages of development include a clinical stage cytosolic phosholipase A2 (cPLA2) inhibitor, histamine H3 receptor antagonists possessing CNS-sparing properties as well as early-stage spleen tyrosine kinase (SYK) inhibitor molecules suitable for topical administration.
25.11.2014 The European biotech IPO slump has finally come to an end. A brand new industry report shows that compared to previous years, the number of biotech IPOs more than doubled in 2014, with London and Paris exchanges leading the pack.
19.11.2014 It’s not every day that a company is pushed into the top ten of its sector, but that day has come for Actavis. Christmas came early for the new pharma giant after completing a US$66bn (€53bn) takeover battle for the Botox manufacturer Allergan.
18.11.2014 Merck KGaA and US rival Pfizer have signed a immuno-oncology alliance worth billions: Merck will share the development and commercialisation of its cancer antibody with its US partner – for €2.3bn.
14.11.2014 Cosily coinciding with World Diabetes Day on 14th November, French biopharma Les Laboratories Servier has struck a US$1bn deal with US pharma Intarcia Therapeutics for the exclusive rights to Intarcia’s unprecedented therapy for type 2 diabetes.
12.11.2014 Glitz and glamour are not words often used to describe science and mathematics. But once a year, celebrities from the science and showbiz world come together at the Breakthough Prizes, a glitzy television bash that honours scientists for their achievements. French life scientist Emmanuelle Charpentier was among this year’s winners.
04.11.2014 Galecto Biotech has entered an agreement with Bristol-Myers Squibb for the acquisition of the company and its lead drug, providing the Swedish company with the potential of reaching over US$400m.